Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First Blood-Based Lung Cancer EGFR Test Gets Green Light

This article was originally published in The Gray Sheet

Executive Summary

FDA has approved the first liquid biopsy test to detect genetic mutations linked to drug response in patients with non-small cell lung cancer. Roche's cobas EGFR Mutation Test v2 could be a game-changer in helping to diagnose certain NSCLC patients without requiring a tumor biopsy, the agency suggests.

You may also be interested in...



2016 Original PMAs And Panel-Track Supplements

A sortable and searchable table of FDA original PMAs and panel-track supplements approved in calendar year 2016, updated monthly. Latest update: approvals through June 30.

Roche Eyes Liquid Biopsy As A Boost To Drug Development, Cancer Monitoring

The Gray Sheet spoke to Roche Molecular Diagnostic's top researcher, Walter Koch, about the promise of liquid biopsy soon after FDA approved its first liquid-biopsy companion diagnostic, Roche's cobas test for the cancer drug Tarceva.

Diagnostics In 2015: Past Trends Coalesce, New Roads Open

The introduction of Apple’s ResearchKit is our top story of the year. Mobile apps and the increasing ability to take measurements of vital signs, gather information on habits and collect other phenotypic measures is rapidly changing thinking about clinical trials design.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT034826

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel